Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (8 quarters reported)
$113M in Q4 2018 → $1.23B now. Hover for any quarter.
As reported for the quarter ended September 30, 2020. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Ngm Biopharmaceuticals Inc | 23.4% | Added 1.8% | 18,017,932 | $287M |
| Revolution Medicines Inc | 22.7% | Unchanged | 7,977,384 | $278M |
| Nurix Therapeutics Inc | 19.2% | New | 6,755,881 | $236M |
| Rapt Therapeutics Inc | 14.8% | Trimmed 17% | 5,630,497 | $181M |
| CP Constellation Pharmceticls I | 10.0% | Unchanged | 6,051,376 | $123M |
| Oric Pharmaceuticals Inc. | 9.7% | Unchanged | 4,768,181 | $119M |
| GO Gritstone Oncology Inc | 0.2% | Trimmed 49% | 869,493 | $2.3M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 7 quarters.
quarter ended September 30, 2020 · filed November 04, 2020
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Nurix Therapeutics Inc | New | +6,755,881 | +$236M | 19.2% |
| Arcus Biosciences Inc | Exited | −1,767,676 | −$43.7M | — |
| Rapt Therapeutics Inc | Trimmed | −1,146,654 | −$36.9M | 14.8% |
| Ngm Biopharmaceuticals Inc | Added | +310,954 | +$4.95M | 23.4% |
| GO Gritstone Oncology Inc | Trimmed | −831,452 | −$2.2M | 0.2% |
quarter ended June 30, 2020 · filed August 12, 2020
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Oric Pharmaceuticals Inc. | New | +4,768,181 | +$161M | 13.5% |
| Arcus Biosciences Inc | Trimmed | −1,773,174 | −$43.9M | 3.7% |
| GO Gritstone Oncology Inc | Trimmed | −1,401,989 | −$9.31M | 0.9% |
| Ngm Biopharmaceuticals Inc | Added | +383,834 | +$7.58M | 29.2% |
quarter ended March 31, 2020 · filed May 07, 2020
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Revolution Medicines Inc | New | +7,977,384 | +$175M | 22.1% |
| Ngm Biopharmaceuticals Inc | Added | +902,315 | +$11.1M | 27.0% |
| CP Constellation Pharmceticls I | Added | +41,674 | +$1.31M | 24.1% |
quarter ended December 31, 2019 · filed February 12, 2020
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Rapt Therapeutics Inc | New | +6,777,151 | +$187M | 22.3% |
| Ngm Biopharmaceuticals Inc | Added | +253,922 | +$4.7M | 36.3% |
quarter ended September 30, 2019 · filed November 14, 2019
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| CP Constellation Pharmceticls I | Added | +1,331,763 | +$8.6M | 12.1% |
| Ngm Biopharmaceuticals Inc | Added | +472,816 | +$6.55M | 69.6% |
quarter ended June 30, 2019 · filed August 14, 2019
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Ngm Biopharmaceuticals Inc | New | +15,694,091 | +$230M | 65.7% |
| ID Immune Design Corp. | Exited | −6,642,942 | −$38.9M | — |
quarter ended March 31, 2019 · filed May 08, 2019
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| CP Constellation Pharmceticls I | Added | +1 | +$14 | 33.8% |
Loading...
